Sample Page
Author:
Shanghai Pride Communication
Posted Date:
May 12, 2026
GIP Moves from Supporting Role to Key Variable: BrightGene Bio-Medical’s Phase III Results Signal Differentiation in Weight Loss Arena
Shanghai Pride Communication
May 12, 2026
19.3% Weight Reduction, 16.5 cm Waist Circumference Decrease, SBP/DBP Reductions of 22.9/12.9 mmHg, 70.7 μmol/L Uric Acid Reduction, and 33.6% Triglyceride Reduction: BGM0504 Demonstrates Comprehensive Cardiometabolic Regulation Capabilities
Shanghai Pride Communication
May 6, 2026
BGM0504 Achieves 19.3% Robust Weight Reduction, 16.5 cm Waist Circumference Decrease, Significant SBP/DBP Improvements of 22.9/12.9 mmHg, and 70.7 μmol/L Uric Acid Reduction; Phase III Trial Meets Primary Endpoint and All Key Secondary Endpoints
Shanghai Pride Communication
May 5, 2026
BrightGene Announces Positive Topline Phase 1 Results of Oral BGM0504 in Obesity in China and the United States
Shanghai Pride Communication
March 25, 2026
